Add to ORKGThe price of prescription drugs lies at the heart of two major public health issues: distributing antiretroviral medicines for use against the global AIDS epidemic and purchasing medications from Canada by U.S. consumers using the Internet. Both situations highlight the need to reduce financial barriers to access to medications, while maintaining incentives to promote pharmaceutical innovation
This article argues that universal access to drugs requires not only collaboration between nations a...
As rising health care expenditures focus government attention on slowing the growth, the pharmaceuti...
Access to affordable prescription drug is the critical mass of any meaningful public health policy. ...
While neoclassical economic theory suggests that arbitrage will undermine global differential pricin...
The price of prescription drugs lies at the heart of two major public health issues: distributing an...
The four papers which follow, presented during an interdisciplinary symposium at the University of C...
This paper seeks to identify and consider ethical issues relating to the international pricing of ph...
This article discusses how pharmaceutical innovation achieves remarkable improvements in human healt...
At last count, global pharmaceutical spending exceeded $750 billion. Unlike most medical products a...
I propose to address briefly two important IP questions from an economic perspective: patented drug ...
High drug prices are creating serious health and fiscal problems in the United States to...
Through much of the last half century, Medicare and Medicaid have not for the most part supported re...
Advocates, activists, and academics have criticized pharmaceutical intellectual property ( pharma IP...
The price of medicines is one of the main barriers to treatment access for many poor people in devel...
To date, much of the academic and policy literature has focused on the impact of intellectual proper...
This article argues that universal access to drugs requires not only collaboration between nations a...
As rising health care expenditures focus government attention on slowing the growth, the pharmaceuti...
Access to affordable prescription drug is the critical mass of any meaningful public health policy. ...
While neoclassical economic theory suggests that arbitrage will undermine global differential pricin...
The price of prescription drugs lies at the heart of two major public health issues: distributing an...
The four papers which follow, presented during an interdisciplinary symposium at the University of C...
This paper seeks to identify and consider ethical issues relating to the international pricing of ph...
This article discusses how pharmaceutical innovation achieves remarkable improvements in human healt...
At last count, global pharmaceutical spending exceeded $750 billion. Unlike most medical products a...
I propose to address briefly two important IP questions from an economic perspective: patented drug ...
High drug prices are creating serious health and fiscal problems in the United States to...
Through much of the last half century, Medicare and Medicaid have not for the most part supported re...
Advocates, activists, and academics have criticized pharmaceutical intellectual property ( pharma IP...
The price of medicines is one of the main barriers to treatment access for many poor people in devel...
To date, much of the academic and policy literature has focused on the impact of intellectual proper...
This article argues that universal access to drugs requires not only collaboration between nations a...
As rising health care expenditures focus government attention on slowing the growth, the pharmaceuti...
Access to affordable prescription drug is the critical mass of any meaningful public health policy. ...